Review



cgrp receptor antagonist rat cgrp8 37  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress cgrp receptor antagonist rat cgrp8 37
    CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP <t>+</t> <t>CGRP8-37</t> (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.
    Cgrp Receptor Antagonist Rat Cgrp8 37, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/Rat+CGRP/pmc12504274-42-7-21
    Average 94 stars, based on 15 article reviews
    cgrp receptor antagonist rat cgrp8 37 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis"

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis

    Journal: Frontiers in Bioengineering and Biotechnology

    doi: 10.3389/fbioe.2025.1641476

    CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP + CGRP8-37 (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.
    Figure Legend Snippet: CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP + CGRP8-37 (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.

    Techniques Used: Double Staining, Control

    CGRP enhances BMSC osteogenic differentiation: (A) Alizarin Red S staining showing calcium nodule formation at days 14 and 21 of osteogenic induction. CGRP treatment resulted in more numerous and deeper-stained orange-red calcified nodules compared to controls. CGRP8-37 and H89 treatments significantly reduced CGRP-induced mineralization enhancement (scale bars: 50 μm). (B) Quantitative analysis of Alizarin Red staining using the cetylpyridinium chloride (CPC) extraction method. CGRP treatment showed 3.7-fold and 3.5-fold increases in mineralization at 14 and 21 days, respectively, compared to controls. Both CGRP8-37 and H89 treatments effectively blocked CGRP-induced mineralization enhancement. (C) Alkaline phosphatase (ALP) staining demonstrating enhanced early osteogenic marker expression at days 4 and 7. Purple precipitates indicate ALP activity (scale bars: 50 μm). CGRP8-37 and H89 treatments inhibited CGRP-induced osteogenic enhancement. (D) Quantitative ALP activity measurements normalized to total protein content. CGRP treatment demonstrated 3.7-fold and 3.9-fold increases in ALP activity at 4 and 7 days, respectively, compared to controls. CGRP + CGRP8-37 and CGRP + H89 groups showed significantly reduced ALP activity compared to CGRP alone, confirming that both receptor blockade and PKA pathway inhibition prevent CGRP’s osteogenic enhancing effects.
    Figure Legend Snippet: CGRP enhances BMSC osteogenic differentiation: (A) Alizarin Red S staining showing calcium nodule formation at days 14 and 21 of osteogenic induction. CGRP treatment resulted in more numerous and deeper-stained orange-red calcified nodules compared to controls. CGRP8-37 and H89 treatments significantly reduced CGRP-induced mineralization enhancement (scale bars: 50 μm). (B) Quantitative analysis of Alizarin Red staining using the cetylpyridinium chloride (CPC) extraction method. CGRP treatment showed 3.7-fold and 3.5-fold increases in mineralization at 14 and 21 days, respectively, compared to controls. Both CGRP8-37 and H89 treatments effectively blocked CGRP-induced mineralization enhancement. (C) Alkaline phosphatase (ALP) staining demonstrating enhanced early osteogenic marker expression at days 4 and 7. Purple precipitates indicate ALP activity (scale bars: 50 μm). CGRP8-37 and H89 treatments inhibited CGRP-induced osteogenic enhancement. (D) Quantitative ALP activity measurements normalized to total protein content. CGRP treatment demonstrated 3.7-fold and 3.9-fold increases in ALP activity at 4 and 7 days, respectively, compared to controls. CGRP + CGRP8-37 and CGRP + H89 groups showed significantly reduced ALP activity compared to CGRP alone, confirming that both receptor blockade and PKA pathway inhibition prevent CGRP’s osteogenic enhancing effects.

    Techniques Used: Staining, Extraction, Marker, Expressing, Activity Assay, Inhibition

    CGRP activates the cAMP/PKA signaling pathway in BMSCs: (A) ELISA quantification of intracellular cAMP levels 30 min post-treatment. CGRP rapidly increased cAMP concentration, blocked by CGRP8-37 and H89. Data represent mean ± SD (n = 6). (B-D) Western blot analysis of PKA and CREB phosphorylation at 30 min. Representative blots and quantitative analysis of p-PKA/PKA and p-CREB/CREB ratios. Data represent mean ± SD. *P < 0.05.
    Figure Legend Snippet: CGRP activates the cAMP/PKA signaling pathway in BMSCs: (A) ELISA quantification of intracellular cAMP levels 30 min post-treatment. CGRP rapidly increased cAMP concentration, blocked by CGRP8-37 and H89. Data represent mean ± SD (n = 6). (B-D) Western blot analysis of PKA and CREB phosphorylation at 30 min. Representative blots and quantitative analysis of p-PKA/PKA and p-CREB/CREB ratios. Data represent mean ± SD. *P < 0.05.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Concentration Assay, Western Blot, Phospho-proteomics

    CGRP enhances biomechanical properties of regenerated bone: three-point bending test results at 6 weeks of consolidation showing (A) ultimate load, (B) energy to failure, and (C) stiffness measurements. CGRP treatment significantly improved all mechanical parameters compared to controls. CGRP8-37 and H89 abolished these beneficial effects. Data represent mean ± SD. *P < 0.05.
    Figure Legend Snippet: CGRP enhances biomechanical properties of regenerated bone: three-point bending test results at 6 weeks of consolidation showing (A) ultimate load, (B) energy to failure, and (C) stiffness measurements. CGRP treatment significantly improved all mechanical parameters compared to controls. CGRP8-37 and H89 abolished these beneficial effects. Data represent mean ± SD. *P < 0.05.

    Techniques Used:

    Related Articles

    Double Staining:

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis
    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).. CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.

    Control:

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis
    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).. CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.

    Staining:

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis
    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).. CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.

    Extraction:

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis
    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).. CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.

    Marker:

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis
    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).. CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.

    Expressing:

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis
    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).. CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.

    Activity Assay:

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis
    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).. CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.

    Inhibition:

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis
    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).. CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.

    Enzyme-linked Immunosorbent Assay:

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis
    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).. CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.

    Concentration Assay:

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis
    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).. CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.

    Western Blot:

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis
    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).. CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.

    Phospho-proteomics:

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis
    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).. CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.CGRP8-37 is a well-characterized competitive antagonist of CGRP receptors that blocks CGRP binding to its receptor complex (CALCRL/RAMP1) without intrinsic agonist activity.



    Similar Products

    cgrp receptor antagonist rat cgrp8 37  (MedChemExpress)
    94
    MedChemExpress cgrp receptor antagonist rat cgrp8 37
    CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP <t>+</t> <t>CGRP8-37</t> (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.
    Cgrp Receptor Antagonist Rat Cgrp8 37, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cgrp+receptor+antagonist+rat+cgrp8+37/Rat+CGRP/pmc12504274-42-7-21
    Average 94 stars, based on 1 article reviews
    cgrp receptor antagonist rat cgrp8 37 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP + CGRP8-37 (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis

    doi: 10.3389/fbioe.2025.1641476

    Figure Lengend Snippet: CGRP protects BMSCs from serum deprivation-induced apoptosis: (A) representative flow cytometric dot plots showing Annexin V-FITC/PI double staining after 24 and 48 h of serum-free culture. Four distinct cell populations are displayed: viable cells (Annexin V − /PI − , lower left quadrant), early apoptotic cells (Annexin V + /PI − , lower right quadrant), late apoptotic cells (Annexin V + /PI + , upper right quadrant), and necrotic cells (Annexin V − /PI + , upper left quadrant). Representative plots show control, CGRP (10 −8 M), CGRP + CGRP8-37 (10 −8 M CGRP + 10 −6 M CGRP8-37), and CGRP + H89 (10 −8 M CGRP + 0.2 μg/mL H89) treatment groups. (B) Quantitative analysis of the total apoptotic rate calculated as the sum of early apoptotic (Annexin V + /PI − ) and late apoptotic (Annexin V + /PI + ) cell percentages. CGRP treatment significantly reduced total apoptosis compared to control. CGRP8-37 and H89 co-treatments abolished CGRP’s protective effects, with apoptosis rates returning to control levels. Data represent mean ± SD from independent experiments (n = 6). *P < 0.05 compared to the control group; *P < 0.05 compared to the CGRP group using one-way ANOVA followed by Tukey’s post hoc test.

    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).

    Techniques: Double Staining, Control

    CGRP enhances BMSC osteogenic differentiation: (A) Alizarin Red S staining showing calcium nodule formation at days 14 and 21 of osteogenic induction. CGRP treatment resulted in more numerous and deeper-stained orange-red calcified nodules compared to controls. CGRP8-37 and H89 treatments significantly reduced CGRP-induced mineralization enhancement (scale bars: 50 μm). (B) Quantitative analysis of Alizarin Red staining using the cetylpyridinium chloride (CPC) extraction method. CGRP treatment showed 3.7-fold and 3.5-fold increases in mineralization at 14 and 21 days, respectively, compared to controls. Both CGRP8-37 and H89 treatments effectively blocked CGRP-induced mineralization enhancement. (C) Alkaline phosphatase (ALP) staining demonstrating enhanced early osteogenic marker expression at days 4 and 7. Purple precipitates indicate ALP activity (scale bars: 50 μm). CGRP8-37 and H89 treatments inhibited CGRP-induced osteogenic enhancement. (D) Quantitative ALP activity measurements normalized to total protein content. CGRP treatment demonstrated 3.7-fold and 3.9-fold increases in ALP activity at 4 and 7 days, respectively, compared to controls. CGRP + CGRP8-37 and CGRP + H89 groups showed significantly reduced ALP activity compared to CGRP alone, confirming that both receptor blockade and PKA pathway inhibition prevent CGRP’s osteogenic enhancing effects.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis

    doi: 10.3389/fbioe.2025.1641476

    Figure Lengend Snippet: CGRP enhances BMSC osteogenic differentiation: (A) Alizarin Red S staining showing calcium nodule formation at days 14 and 21 of osteogenic induction. CGRP treatment resulted in more numerous and deeper-stained orange-red calcified nodules compared to controls. CGRP8-37 and H89 treatments significantly reduced CGRP-induced mineralization enhancement (scale bars: 50 μm). (B) Quantitative analysis of Alizarin Red staining using the cetylpyridinium chloride (CPC) extraction method. CGRP treatment showed 3.7-fold and 3.5-fold increases in mineralization at 14 and 21 days, respectively, compared to controls. Both CGRP8-37 and H89 treatments effectively blocked CGRP-induced mineralization enhancement. (C) Alkaline phosphatase (ALP) staining demonstrating enhanced early osteogenic marker expression at days 4 and 7. Purple precipitates indicate ALP activity (scale bars: 50 μm). CGRP8-37 and H89 treatments inhibited CGRP-induced osteogenic enhancement. (D) Quantitative ALP activity measurements normalized to total protein content. CGRP treatment demonstrated 3.7-fold and 3.9-fold increases in ALP activity at 4 and 7 days, respectively, compared to controls. CGRP + CGRP8-37 and CGRP + H89 groups showed significantly reduced ALP activity compared to CGRP alone, confirming that both receptor blockade and PKA pathway inhibition prevent CGRP’s osteogenic enhancing effects.

    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).

    Techniques: Staining, Extraction, Marker, Expressing, Activity Assay, Inhibition

    CGRP activates the cAMP/PKA signaling pathway in BMSCs: (A) ELISA quantification of intracellular cAMP levels 30 min post-treatment. CGRP rapidly increased cAMP concentration, blocked by CGRP8-37 and H89. Data represent mean ± SD (n = 6). (B-D) Western blot analysis of PKA and CREB phosphorylation at 30 min. Representative blots and quantitative analysis of p-PKA/PKA and p-CREB/CREB ratios. Data represent mean ± SD. *P < 0.05.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis

    doi: 10.3389/fbioe.2025.1641476

    Figure Lengend Snippet: CGRP activates the cAMP/PKA signaling pathway in BMSCs: (A) ELISA quantification of intracellular cAMP levels 30 min post-treatment. CGRP rapidly increased cAMP concentration, blocked by CGRP8-37 and H89. Data represent mean ± SD (n = 6). (B-D) Western blot analysis of PKA and CREB phosphorylation at 30 min. Representative blots and quantitative analysis of p-PKA/PKA and p-CREB/CREB ratios. Data represent mean ± SD. *P < 0.05.

    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).

    Techniques: Enzyme-linked Immunosorbent Assay, Concentration Assay, Western Blot, Phospho-proteomics

    CGRP enhances biomechanical properties of regenerated bone: three-point bending test results at 6 weeks of consolidation showing (A) ultimate load, (B) energy to failure, and (C) stiffness measurements. CGRP treatment significantly improved all mechanical parameters compared to controls. CGRP8-37 and H89 abolished these beneficial effects. Data represent mean ± SD. *P < 0.05.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: CGRP-dependent molecular signaling drives bone marrow stem cell osteogenesis in distraction osteogenesis

    doi: 10.3389/fbioe.2025.1641476

    Figure Lengend Snippet: CGRP enhances biomechanical properties of regenerated bone: three-point bending test results at 6 weeks of consolidation showing (A) ultimate load, (B) energy to failure, and (C) stiffness measurements. CGRP treatment significantly improved all mechanical parameters compared to controls. CGRP8-37 and H89 abolished these beneficial effects. Data represent mean ± SD. *P < 0.05.

    Article Snippet: Rat α-calcitonin gene-related peptide (rat α-CGRP, HY-P0203), CGRP receptor antagonist rat CGRP8-37 (HY-P0209), and PKA inhibitor H89 (HY-15979) were purchased from MCE (China).

    Techniques: